Why Is CRISPR Therapeutics AG (CRSP) Up 0.2% Since Last Earnings Report?

1
1
Favorite

Why Is CRISPR Therapeutics AG (CRSP) Up 0.2% Since Last Earnings Report?

Zacks2022-12-02

It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 0.2% in that time frame, underperforming the S&P 500. Will the recent positive trend...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

in_deep_red
·2022-12-05
Vgood!
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2288602852?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UACuRym2G7Sc_7yqOtSLVQ--~B/aD0yMzUxO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0","is_english":true,"pubTime":"2022-12-02 00:31","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2288602852","market":"us","top_or_hot":-1,"title":"Why Is CRISPR Therapeutics AG (CRSP) Up 0.2% Since Last Earnings Report?","media":"Zacks","content":"<div>\n<p>It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 0.2% in that time frame, underperforming the S&P 500.\nWill the recent positive trend...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-crispr-therapeutics-ag-crsp-163104925.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is CRISPR Therapeutics AG (CRSP) Up 0.2% Since Last Earnings Report?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is CRISPR Therapeutics AG (CRSP) Up 0.2% Since Last Earnings Report?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-12-02 00:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-crispr-therapeutics-ag-crsp-163104925.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 0.2% in that time frame, underperforming the S&P 500.\nWill the recent positive trend...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-crispr-therapeutics-ag-crsp-163104925.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AG","symbol_name":"First Majestic Silver Corporation","start_time":0,"source_url":"https://finance.yahoo.com/news/why-crispr-therapeutics-ag-crsp-163104925.html","article_id":"2288602852","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UACuRym2G7Sc_7yqOtSLVQ--~B/aD0yMzUxO3c9MzAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/zacks.com/c65fb4556b91b6c9dc83e4eff25fede0"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2288602852","pubTimestamp":1669912264,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares h","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"AG":"First Majestic Silver Corporation","CRSP":"CRISPR Therapeutics AG"},"translate_title":"为什么CRISPR Therapeutics AG（CRSP）自上次财报以来上涨了0.2%？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AG":1,"CRSP":1},"content_text":"It has been about a month since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 0.2% in that time frame, underperforming the S&P 500.\nWill the recent positive trend continue leading up to its next earnings release, or is CRISPR Therapeutics AG due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. \nQ3 Earnings Top, Sales Lag Estimates\nCRISPR Therapeutics reported a net loss per share of $2.24 in third-quarter 2022, narrower than the Zacks Consensus Estimate and our estimate of a loss of $2.30 and $2.44. The company had posted a loss of $1.67 per share in the year-ago period.\nCRISPR Therapeutics' total revenues, comprising grants and collaboration revenues, came in at $0.1 million in the third quarter compared with $0.82 million reported in the year-ago period. Revenues substantially missed the Zacks Consensus Estimate and our estimate of $4.0 million and $6.0 million, respectively.\nQuarter in Detail\nFor the reported quarter, research and development expenses were $116.6 million, up 40% from the year-ago figure to support the development of pipeline programs and costs related to the increased headcounts to support the developmental programs.\nGeneral and administrative expenses rose 14% year over year to $27 million.\nCollaboration expenses for the third quarter reached $38.9 million, up 73% year-over-year. The rise was driven by increased pre-commercial and manufacturing costs associated with CRISPR’s hemoglobinopathies program under the Vertex collaboration.\nAs of Sep 30, 2022, the company had cash, cash equivalents and marketable securities of $1.97 billion compared with $2.07 billion as of Jun 30, 2022.\nHow Have Estimates Been Moving Since Then?\nIt turns out, fresh estimates flatlined during the past month.\nVGM Scores\nCurrently, CRISPR Therapeutics AG has a poor Growth Score of F, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.\nOverall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.\nOutlook\nCRISPR Therapeutics AG has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.\nPerformance of an Industry Player\nCRISPR Therapeutics AG belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Vertex Pharmaceuticals (VRTX), has gained 2.1% over the past month. More than a month has passed since the company reported results for the quarter ended September 2022.\nVertex reported revenues of $2.33 billion in the last reported quarter, representing a year-over-year change of +17.7%. EPS of $4.01 for the same period compares with $3.56 a year ago.\nFor the current quarter, Vertex is expected to post earnings of $3.55 per share, indicating a change of +5.3% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.\nVertex has a Zacks Rank #2 (Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of A.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nCRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report\nVertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9967911873,"gmtCreate":1670247603593,"gmtModify":1676538328622,"author":{"id":"3586741802190308","authorId":"3586741802190308","name":"in_deep_red","avatar":"https://static.tigerbbs.com/b428b6bee1937061822da4d8a206e8cb","vip":1,"crmLevel":8,"crmLevelSwitch":1,"idStr":"3586741802190308","authorIdStr":"3586741802190308"},"htmlText":"Vgood!","listText":"Vgood!","text":"Vgood!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9967911873","repostId":2288602852,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}